FY2024 Earnings Forecast for IPSC Issued By Leerink Partnrs

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Leerink Partnrs lifted their FY2024 EPS estimates for Century Therapeutics in a research report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will earn ($0.09) per share for the year, up from their previous estimate of ($1.75). The consensus estimate for Century Therapeutics' current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Century Therapeutics' Q4 2024 earnings at $0.93 EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.54) EPS and FY2028 earnings at ($1.32) EPS.

A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler lowered their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating on the stock in a report on Monday, December 30th. Guggenheim restated a "buy" rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Chardan Capital lowered their price target on shares of Century Therapeutics from $17.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $10.00.

Century Therapeutics Price Performance

Shares of Century Therapeutics stock traded down $0.01 on Monday, reaching $0.75. 1,179,497 shares of the company traded hands, compared to its average volume of 512,291. Century Therapeutics has a 52 week low of $0.68 and a 52 week high of $5.51. The company has a 50 day moving average of $0.94 and a 200 day moving average of $1.33. The firm has a market capitalization of $63.68 million, a PE ratio of -0.40 and a beta of 1.73.

Institutional Trading of Century Therapeutics

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in Century Therapeutics in the third quarter valued at approximately $27,000. Geode Capital Management LLC increased its holdings in shares of Century Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company's stock worth $1,002,000 after buying an additional 23,413 shares during the last quarter. Jane Street Group LLC raised its position in shares of Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company's stock valued at $49,000 after buying an additional 29,992 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after acquiring an additional 34,466 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Century Therapeutics in the fourth quarter worth $36,000. Institutional investors own 50.20% of the company's stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.